Observatorio de I+D+i UPM

Memorias de investigación
Proyecto de I+D+i:
NeoMARK: ICT Enabled Prediction of Cancer Recurrence
Año:2011
Áreas de investigación
Datos
Descripción

NeoMark is a EC-FP7-IST project investigating an innovative strategy and develops the appropriate technologies to identify person-specific and disease-specific biomarkers for tumors, to assess recurrence risk and early identify relapses during follow-up. The project validates this approach Oral Squamous Cell Carcinoma (OSCC) that represents about 5% of all cancers, with a recurrence rate of about 25% to 50% over five years, 90% of which within two years from surgery. Knowing in advance which patients have the higher risk of disease reoccurrence would enable less invasive and earlier treatments, with the potential to improve patients survival and quality of life. A new approach to this problem requires the collection, aggregation and analysis of large sets of clinical data together with information on the biology of the disease and an advanced study of affected tissues by novel image-interpretation techniques to be applied on different diagnostic exams. NeoMark provides the powerful computational resources and accurate and refined analysis algorithms necessary to process this multi-dimensional and large amount of data, to find the characterizing factors, or biomarkers, uniquely identifying the OSCC disease, like a personalized ID card (or bioprofile) of OSCC for each specific patient. The NeoMark system will be able to detect the presence of such bioprofile from patient´s data collected at follow-up, even when no signs of relapse are evident, so early triggering therapeutic actions. NeoMark also intends to identify a reduced set of most relevant genomic biomarkers for each individual patient, which could be assessed by means of a portable RT-PCR lab-on-chip device for a fast relapse risk evaluation, based on genomic data from blood or tissue only, developed by ST Microelectronics. This innovative device would constitute, once approved through wide clinical trials, a powerful and low-cost diagnostic equipment.

Internacional
Si
Tipo de proyecto
Proyectos y convenios en convocatorias públicas competitivas
Entidad financiadora
Comisión Europea
Nacionalidad Entidad
BELGICA
Tamaño de la entidad
Grande
Fecha concesión
14/05/2008
Participantes
  • Participante: Marta Ortega Portillo (UPM)
  • Director: Maria Teresa Arredondo Waldmeyer (UPM)
  • Participante: Cecilia Vera Muñoz (UPM)
  • Participante: Angel Esteban Orobio (UPM)
  • Participante: Giuseppe Fico (UPM)
  • Participante: Manuel Ottaviano . (UPM)
  • Participante: Laura Pastor Sanz (UPM)
  • Participante: Gloria Ruiz Cadenas (UPM)
  • Participante: Dario Salvi . (UPM)
  • Participante: Juan Luis Villalar González (UPM)
  • Participante: Juan Bautista Montalvá Colomer (UPM)
  • Participante: Mario Pansera . (UPM)
  • Participante: Juan Jacobo Estrada Paz (UPM)
  • Participante: Patricia Abril Jimenez (UPM)
  • Participante: Eugenio Gaeta (UPM)
  • Participante: Viveca Jimenez Mixco (UPM)
  • Participante: Lydia Gardon Ríos (UPM)
  • Participante: Antonella Arca . (UPM)
  • Participante: Mª de las Mercedes Fernandez Rodriguez (UPM)
  • Participante: Alejandro Cordon Ureña (UPM)
  • Participante: Maria Fernanda Cabrera Umpierrez (UPM)
  • Participante: Abelardo Leon Gonzalez (UPM)
  • Participante: Alessio Fioravanti . (UPM)
  • Participante: Ignacio Peinado Martínez (UPM)
  • Participante: Ignacio Martin Siles (UPM)
  • Participante: Paloma Rodriguez Horche (UPM)
Grupos de investigación, Departamentos, Centros e Institutos de I+D+i relacionados
  • Centro o Instituto I+D+i: Centro de tecnología Biomédica CTB
  • Grupo de Investigación: Life Supporting Technologies (Tecnologías de Apoyo a la Vida)
  • Departamento: Tecnología Fotónica y Bioingeniería
S2i 2021 Observatorio de investigación @ UPM con la colaboración del Consejo Social UPM
Cofinanciación del MINECO en el marco del Programa INNCIDE 2011 (OTR-2011-0236)
Cofinanciación del MINECO en el marco del Programa INNPACTO (IPT-020000-2010-22)